Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2000

Primary Completion Date

December 31, 2006

Study Completion Date

April 30, 2007

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

carboplatin

DRUG

pyrazoloacridine

Trial Locations (23)

32224

Mayo Clinic, Jacksonville

54301

CCOP - St. Vincent Hospital Cancer Center, Green Bay, Green Bay

55416

CCOP - Metro-Minnesota, Saint Louis Park

55805

CCOP - Duluth, Duluth

55905

Mayo Clinic Cancer Center, Rochester

56303

CentraCare Health Plaza, Saint Cloud

57104

CCOP - Sioux Community Cancer Consortium, Sioux Falls

57709

Rapid City Regional Hospital, Rapid City

58122

CCOP - Merit Care Hospital, Fargo

58201

Altru Cancer Center, Grand Forks

61602

CCOP - Illinois Oncology Research Association, Peoria

61801

CCOP - Carle Cancer Center, Urbana

68106

CCOP - Missouri Valley Cancer Consortium, Omaha

70121

CCOP - Ochsner, New Orleans

85259-5404

CCOP - Scottsdale Oncology Program, Scottsdale

52403-1206

CCOP - Cedar Rapids Oncology Project, Cedar Rapids

50309-1016

CCOP - Iowa Oncology Research Association, Des Moines

51101-1733

Siouxland Hematology-Oncology, Sioux City

67214-3882

CCOP - Wichita, Wichita

58501-5505

Medcenter One Health System, Bismarck

43623-3456

CCOP - Toledo Community Hospital, Toledo

17822-2001

CCOP - Geisinger Clinic and Medical Center, Danville

S4T 7T1

Allan Blair Cancer Centre, Regina

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00005976 - Pyrazoloacridine Plus Carboplatin in Treating Patients With Recurrent Glioma | Biotech Hunter | Biotech Hunter